Adaptimmune Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Share-based compensation

Share-based compensation

6 Months Ended

Jun. 30, 2025

Note 11 — Share-based compensation

The following table shows the total share-based compensation expense included in the unaudited consolidated statements of operations (in thousands):


		Three months ended			Six months ended
		June 30,			June 30,
	2025		2024		2025		2024
Research and development	$	305	$	994	$	173	$	1,808
Selling, general and administrative		1,016		2,063		1,817		4,352
	$	1,321	$	3,057	$	1,990	$	6,160

The following table shows information about share options and options which have a nominal exercise price (similar to restricted stock units (RSUs)) granted:


		Three months ended			Six months ended
		June 30,			June 30,
	2025		2024		2025		2024
Number of options over ordinary shares granted		24,711,600		1,795,872		24,711,600		43,982,424
Weighted average fair value of ordinary shares options	$	0.07	$	0.19	$	0.07	$	0.12
Number of additional options with a nominal exercise price granted		24,944,376		2,540,640		24,944,376		30,655,824
Weighted average fair value of options with a nominal exercise price	$	0.10	$	0.24	$	0.10	$	0.15